What is the appropriate pain management plan for a patient with pain following a stepladder injury?

Stepladder Pain Management

For acute musculoskeletal injuries from stepladder falls, start immediately with oral NSAIDs or acetaminophen as first-line therapy, add topical NSAIDs for localized pain, and reserve opioids only for severe pain that fails non-opioid management—using the lowest effective dose of immediate-release formulations for the shortest duration possible. 1, 2

Initial Pain Management Algorithm (First 2 Hours)

First-Line Pharmacologic Options:

• Acetaminophen alone: Provides moderate pain reduction (1.03 cm on 10-cm scale) with high safety profile 1
• Oral NSAIDs: Equally effective (0.93 cm reduction) with moderate-certainty evidence 1
• Topical NSAIDs: Comparable efficacy (1.02 cm reduction) with fewer systemic side effects—particularly useful for localized extremity injuries 1
• Combination therapy: Acetaminophen plus oral diclofenac shows slightly better early pain control (1.11 cm reduction) 1

When to Add Opioids:

Only consider opioids if pain remains severe (NRS >7) after non-opioid therapy. Acetaminophen plus opioids showed only minimal additional benefit (0.50 cm reduction) in high-certainty evidence 1. This small effect size must be weighed against opioid risks.

Sustained Pain Management (Days 1-7)

Maintain Non-Opioid Foundation:

• Continue acetaminophen (1.07 cm pain reduction at 1-7 days) 1
• Continue oral NSAIDs (0.99 cm reduction) or topical NSAIDs (1.08 cm reduction) 1
• Both show sustained moderate-certainty evidence for effectiveness

Critical Pitfall to Avoid:

Do NOT use tramadol alone—moderate-certainty evidence shows it provides no statistically significant pain reduction compared to placebo at <2 hours 1. Similarly, acetaminophen plus ibuprofen plus oxycodone showed no significant benefit 1.

Multimodal Approach for Severe Injuries

Non-Pharmacologic Adjuncts:

• Massage therapy: Moderate-certainty evidence for early pain relief (0.70 cm reduction) 1
• TENS (transcutaneous electrical nerve stimulation): Low-certainty evidence but clinically meaningful reduction (1.94 cm at <2 hours, 1.18 cm at 1-7 days) 1, 2
• Ice and elevation: Recommended as standard physical strategies 2

Regional Anesthesia Consideration:

For severe extremity injuries (fractures, multiple trauma sites), peripheral nerve blocks significantly reduce opioid consumption and should be considered early 3, 2. This is particularly valuable in hemodynamically stable patients.

Opioid Prescribing When Necessary

Key Principles:

1. Use immediate-release formulations only 2
2. Prescribe lowest effective dose for shortest duration 2
3. Single prescriber model for patients already on chronic opioids 2
4. Query prescription drug monitoring program before prescribing 2
5. No tapering plan mentioned in 78% of discharge reports in one study—this is a critical gap that must be addressed 4

Hemodynamic Considerations:

In hemodynamically unstable patients from severe trauma, fentanyl is superior to other opioids due to minimal hemodynamic effects 5. Ketamine at analgesic doses is an attractive alternative 6, 5.

Assessment Requirements

• Use Numeric Rating Scale (NRS) 0-10 for pain assessment—validated in emergency settings with 96% applicability 6
• Assess pain regularly with short, validated tools for inpatients 2
• Expect substantial pain: 38% of trauma patients report average resting pain >3 for two weeks post-injury 4

What NOT to Do

• Avoid supervised rehabilitation in first week—moderate-certainty evidence shows it paradoxically increases pain (1.06 cm) at 1-7 days 1
• Avoid muscle relaxants alone: Cyclobenzaprine combinations showed no benefit 1
• Avoid glucosamine: No pain reduction at 1-7 days despite moderate-certainty evidence 1

Discharge Planning

Critical gap in current practice: Most patients receive opioid prescriptions at discharge without cessation plans 4. Your discharge prescription must include:

• Specific duration (typically 3-7 days maximum)
• Explicit tapering instructions
• Transition plan back to non-opioid analgesia
• Follow-up pain assessment timing

The evidence strongly supports that non-opioid multimodal analgesia should be the foundation, with opioids reserved as short-term adjuncts only when pain severity justifies the risks 1, 7, 2.